Contents

Current Pharmaceutical Design, Volume 16 - Number 3

Editorial [Hot topic: New Generation Cancer Vaccines: From Tumor Immunology to Clinical Applications (Executive Editor: Simone Mocellin)]

, 16(3): 253 - 254

Simone Mocellin


DOI: 10.2174/138161210790170157




Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells

, 16(3): 255 - 267

Norberto W. Zwirner, Diego O. Croci, Carolina I. Domaica and Gabriel A. Rabinovich


DOI: 10.2174/138161210790170175




Circumventing Immune Tolerance Through Epigenetic Modification

, 16(3): 268 - 276

Jason A. Dubovsky, Alejandro Villagra, John J. Powers, Hong-Wei Wang, Javier Pinilla-Ibarz and Eduardo M. Sotomayor


DOI: 10.2174/138161210790170120




Metabolic Immune Restraints: Implications for Anticancer Vaccines

, 16(3): 277 - 291

Simone Mocellin


DOI: 10.2174/138161210790170139




Cancer Vaccines: Emphasis on Pediatric Cancers

, 16(3): 292 - 299

Terri Guinipero and Olivera J. Finn


DOI: 10.2174/138161210790170148




Idiotype Vaccines for Human B-Cell Malignancies

, 16(3): 300 - 307

S. Inoges, A. Lopez-Diaz de Cerio, E. Soria, H. Villanueva, F. Pastor and M. Bendandi


DOI: 10.2174/138161210790170111




Editorial [Hot topic: The Search of Targets for Novel Antipsychotic Drugs (Executive Editor: Akihiro Takano)]

, 16(3): 308

Akihir Takano


DOI: 10.2174/138161210790170076




Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists

, 16(3): 309 - 322

Richard J. Radek, Kathy L. Kohlhaas, Lynne E. Rueter and Eric G. Mohler


DOI: 10.2174/138161210790170166




Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology

, 16(3): 323 - 343

Morten S. Thomsen, Henrik H. Hansen, Mikkelsen B. Timmerman and Jens D. Mikkelsen


DOI: 10.2174/138161210790170094




Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia

, 16(3): 344 - 357

Lee A. Dawson and Paul W. Smith


DOI: 10.2174/138161210790170067




Conditioned Avoidance Response in the Development of New Antipsychotics

, 16(3): 358 - 370

M-L. G. Wadenberg


DOI: 10.2174/138161210790170085




The Application of PET Technique for the Development and Evaluation of Novel Antipsychotics

, 16(3): 371 - 377

Akihiro Takano


DOI: 10.2174/138161210790170102




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science